BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27581096)

  • 1. The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.
    Chen L; Chen Y; Li B
    Sci Rep; 2016 Sep; 6():32126. PubMed ID: 27581096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
    Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
    World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.
    Nagahara A; Suzuki T; Nagata N; Sugai N; Takeuchi Y; Sakurai K; Miyamoto M; Inoue K; Akiyama J; Mabe K; Konuma I; Kamada T; Haruma K
    J Gastroenterol; 2014 Dec; 49(12):1536-47. PubMed ID: 24366288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
    Pace F; Coudsy B; DeLemos B; Sun Y; Xiang J; LoCoco J; Casalini S; Li H; Pelosini I; Scarpignato C
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):845-51. PubMed ID: 21900784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of rabeprazole in gastroesophageal reflux disease: report of a multicenter study.
    Kar P; Chandrashekar N; Devi S; Bhatia SJ; Alvares JF; Taneja A; Towar A
    Indian J Gastroenterol; 2003; 22(4):153. PubMed ID: 12962446
    [No Abstract]   [Full Text] [Related]  

  • 6. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
    Lim PW; Goh KL
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
    Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI
    Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
    Liu XH; Ke MY; Song ZQ; Luo JY; Yuan YZ; Hou XH; Zhu YL; Sun J; Zha H
    Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):818-21. PubMed ID: 16316559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
    Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
    Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
    Barberio B; Visaggi P; Savarino E; de Bortoli N; Black CJ; Ford AC
    Neurogastroenterol Motil; 2023 Jan; 35(1):e14469. PubMed ID: 36153790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
    Oda K; Iwakiri R; Hara M; Watanabe K; Danjo A; Shimoda R; Kikkawa A; Ootani A; Sakata H; Tsunada S; Fujimoto K
    Dig Dis Sci; 2005 Oct; 50(10):1921-6. PubMed ID: 16187198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?
    Miwa H; Takubo K; Shimatani T; Furuta T; Oshima T; Tanaka J; Aida J; Ito M; Kurosawa S; Joh T; Wada T; Habu Y; Watanabe Y; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol Hepatol; 2013 Mar; 28(3):479-87. PubMed ID: 22989221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
    Dean BB; Siddique RM; Yamashita BD; Bhattacharjya AS; Ofman JJ
    Am J Health Syst Pharm; 2001 Jul; 58(14):1338-46. PubMed ID: 11471482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis.
    Zhang JX; Ji MY; Song J; Lei HB; Qiu S; Wang J; Ai MH; Wang J; Lv XG; Yang ZR; Dong WG
    World J Gastroenterol; 2013 Dec; 19(45):8408-19. PubMed ID: 24363534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis.
    Weijenborg PW; Cremonini F; Smout AJ; Bredenoord AJ
    Neurogastroenterol Motil; 2012 Aug; 24(8):747-57, e350. PubMed ID: 22309489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of proton pump inhibitors in nonerosive reflux disease.
    Dean BB; Gano AD; Knight K; Ofman JJ; Fass R
    Clin Gastroenterol Hepatol; 2004 Aug; 2(8):656-64. PubMed ID: 15290657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
    Haddad I; Kierkus J; Tron E; Ulmer A; Hu P; Sloan S; Silber S; Leitz G
    J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):798-807. PubMed ID: 23863328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
    Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
    J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.